Search Results
May 31, 2026, 08:01 ET Lilly's Retevmo (selpercatinib) demonstrated an 83% reduction in the risk of disease recurrence or death as adjuvant therapy for people with early-stage RET fusion-positive lung cancer
disease recurrence in the central nervous system (CNS) as assessed by investigator and BICR, progression-free survival on the next line of treatment (PFS2), positive predictive value (PPV) of RET tests from investigator-identified laboratories with respect to the Lilly-designated RET test,
More news about: Eli Lilly and Company
May 30, 2026, 20:09 ET Dizal Presents Positive NSCLC Data for Fourth-Generation EGFR TKI DZD6008 and Golidocitinib in Combination with Anti-PD-1 at ASCO 2026
DZD6008 treatment. Higher response rate is expected with longer treatment.Tumor response is durable, with 6 months progression free survival (PFS) rates at 70.6% and 61.8%, respectively for 40 mg and 60 mg cohorts. The median duration of response (DoR) was not reached.Excellent blood-brain
More news about: Dizal Pharmaceutical
May 30, 2026, 20:00 ET Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab for First-Line Treatment of PD-L1-Positive NSCLC Published in The Lancet
prolongs progression-free survival (PFS) and reduces the risk of disease progression or death, with a hazard ratio (HR) of 0.35. Consistent PFS benefits were observed across all prespecified subgroups, including by PD-L1 expression level and histological type, with PFS HRs of 0.47 and 0.28 for the PD-L1
More news about: Kelun-Biotech
May 29, 2026, 23:32 ET The Results of Phase III OptiTROP-Lung05 Study of Sacituzumab Tirumotecan (sac-TMT) Presented as an ASCO Oral Presentation and Simultaneously Published in The Lancet
study demonstrated that:Progression-free survival (PFS) showed statistically significant and clinically meaningful benefit in sac-TMT plus pembrolizumab compared with pembrolizumab alone. The median PFS assessed by blinded independent central review (BICR) was not reached (NR)
More news about: Kelun-Biotech
May 29, 2026, 08:52 ET Dizal Announces Phase 3 WU-KONG28 Results: ZEGFROVY® (Sunvozertinib) Outperforms Platinum-Doublet Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation-Positive Non-Small Cell Lung Cancer
improvement in progression-free survival (PFS), the primary endpoint of the study, as assessed by blinded independent central review (BICR). The overall safety profile was consistent with previous studies, no new safety finding.Median PFS was 10.3
More news about: Dizal Pharmaceutical
May 29, 2026, 08:18 ET New TECVAYLI® (teclistamab-cqyv) data demonstrate superior progression-free and overall survival as early as first relapse in multiple myeloma
lenalidomide and CD38 monoclonal antibody. The primary endpoint is PFS; secondary endpoints include complete response or better (≥CR), duration of response (DoR), time to next treatment (TTNT), progression-free survival on next line of therapy (PFS2), overall survival (OS), safety, and patient-reported outcomes.About
More news about: Johnson & Johnson
May 29, 2026, 08:00 ET AbbVie Announces European Commission Authorization of Expanded Label for VENCLYXTO® (venetoclax) to Include Additional Combinations in Previously Untreated Chronic Lymphocytic Leukemia
35% versus chemoimmunotherapy. Median progression-free survival (PFS) was not reached versus 47.6 months for chemoimmunotherapy. The triplet regimen including obinutuzumab also demonstrated clinically meaningful efficacy, with median PFS likewise not reached. The safety profiles of the combination regimens
More news about: AbbVie
May 29, 2026, 08:00 ET AbbVie Announces European Commission Authorization of Expanded Label for VENCLYXTO® (venetoclax) to Include Additional Combinations in Previously Untreated Chronic Lymphocytic Leukemia
35% versus chemoimmunotherapy. Median progression-free survival (PFS) was not reached versus 47.6 months for chemoimmunotherapy. The triplet regimen including obinutuzumab also demonstrated clinically meaningful efficacy, with median PFS likewise not reached. The safety profiles of the combination regimens
More news about: AbbVie
May 28, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN
locally advanced or metastatic melanoma" "did not each statistical significance for the primary endpoint of improvement in progression-free survival (PFS) compared to pembrolizumab (PD-1 inhibitor) monotherapy." On this news, Regeneron's stock price fell $68.57 per share, or 9.82%, to close at $629.68
More news about: Pomerantz LLP
May 28, 2026, 09:05 ET Gold Above $4,500 And A Permitted Tanzanian Project Heading For First Pour: How A Sub-$0.20 Junior Is Positioned For The Next Phase
market, or through other investment vehicles. Cautionary Note on Production Decision: Although Imwelo has been the subject of JORC-compliant PEA, PFS and updated PFS work, these foreign-code studies are not current under NI 43-101. The Company has not completed a feasibility study on Imwelo that establishes
More news about: Equity Insider
May 28, 2026, 08:54 ET Florida Cancer Specialists & Research Institute Advances the Future of Cancer Care
factor receptor 2 (HER2) immunohistochemistry (IHC) 3+ solid tumors: DESTINY-PanTumor04.Efficacy prediction for progression-free survival (PFS) and overall survival (OS) by genomic instability score (GIS) cutoffs in patients (pts) with advanced ovarian cancer (aOC): Post hoc results from the
More news about: Florida Cancer Specialists & Research Institute
May 28, 2026, 06:30 ET MAYFAIR GOLD CONTINUES TO BUILD PROJECT TEAM WITH ADDITION OF DIRECTOR OF PROJECTS
Study (the "PFS")1 is to develop the project under the provincial permitting process, targeting the higher-grade 1 million ounce mineral reserve (25.1Mt at an average grade of 1.29g/t) sitting near-surface, highlighting the optionality and scalability provided by the deposit. The PFS also outlines
More news about: Mayfair Gold Corp.
May 27, 2026, 20:00 ET Antengene Receives CDE Endorsement to Initiate Pivotal Phase III CLINCH-3 Study of ATG-022 in CLDN18.2+ Advanced Gastric/GEJ Cancer
gastroesophageal junction adenocarcinoma. The primary endpoints of the study are progression-free survival as assessed by independent review committee (PFS by IRC) and overall survival (OS). Secondary endpoints include objective response rate (ORR), duration of response (DOR), disease control rate (DCR),
More news about: Antengene Corporation Limited
May 27, 2026, 17:00 ET Phase 3 HERIZON-GEA-01 Results Published in The New England Journal of Medicine Show Durable and Consistent Survival Benefit with Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2+ Locally Advanced or Metastatic GEA
unprecedented progression-free survival (PFS) and overall survival (OS) outcomes in a global Phase 3 trial.As previously reported, both zanidatamab-containing combinations significantly improved PFS compared with trastuzumab plus chemotherapy (median PFS 12.4 months versus 8.1 months;
More news about: Jazz Pharmaceuticals plc
May 27, 2026, 07:00 ET Defense Metals and Hanwha Corporation Sign Non-Binding Memorandum of Understanding To Advance Domestic Rare Earth Supply Chain
reserve, as detailed in the Company's 2025 Pre Feasibility Study ("PFS"; refer to Company News Release April 7th, 2025) prepared in accordance with National Instrument 43-101 Standards of Disclosure for Mineral Projects. The PFS shows the economic potential of the deposit and supports future
More news about: Defense Metals Corp.
May 27, 2026, 07:00 ET BioLineRx Reports First Quarter 2026 Financial Results and Provides Corporate Update
chemotherapy (gemcitabine and nab-paclitaxel).A prespecified interim/futility analysis is planned when 40% of progression-free survival (PFS) events are observed, which the Company continues to anticipate will occur in 2026.APHEXDA Performance Update
More news about: BioLineRx Ltd.
May 27, 2026, 06:40 ET Dizal's ZEGFROVY® (Sunvozertinib) New Drug Application Accepted and Granted Priority Review by China National Medical Products Administration for First-Line Treatment of EGFR Exon 20 Insertion-Mutated Non-Small Cell Lung Cancer
EGFR exon20ins. The study met its primary endpoint with statistically significant and clinically meaningful improvement in Progression Free Survival (PFS). The detailed data will be presented as a Late-Breaking Abstract (LBA) oral presentation at the upcoming 2026 American Society of Clinical Oncology
More news about: Dizal Pharmaceutical
May 27, 2026, 05:38 ET Fosun International Recognized on Fortune's 2026 "Most Admired Chinese Companies" List
NF1-PN.Furthermore, Henlius' HLX43, a potential best-in-class broad-spectrum anti-tumor PD-L1 ADC, will have its key subgroup progression-free survival (PFS) data in non-small cell lung cancer (NSCLC) presented for the first time in a Rapid Oral Presentation at ASCO, further supporting its clinical potential
More news about: Fosun
May 27, 2026, 05:14 ET WuXi Biologics Achieves GMP Release of 18th Drug Product Facility, Advancing Integrated Drug Substance to Drug Product Capabilities
large-volume device solutions, the company offers a full range of delivery formats, including liquid and lyophilized vial formulations, pre-filled syringes (PFS), dual-chamber cartridges (DCC), and a variety of safety and automated combination products. These capabilities are supported by coordinated operations
More news about: WuXi Biologics
May 26, 2026, 10:35 ET Tungsten's 557% Run Meets a District-Scale Critical-Minerals Story in British Columbia
American: GMTL) provided a Pre-Feasibility Study progress update for its 100%-owned Pilot Mountain tungsten project in Nevada on May 6, 2026. The PFS is being supported by a US$6.2 million U.S. Department of War Defense Production Act Title III investment in Guardian Metal's wholly-owned
More news about: Equity Insider
May 26, 2026, 08:00 ET Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa® Gene Therapy Published at the 2026 ASCO Annual Meeting
correlated with prolonged PFS (p=0.05), and PTEN H-scores below 100 correlated with prolonged PFS (p=0.03).In patients with SCLC, Trop-2 H-scores were universally low, and thus non-evaluable. PTEN H-scores in patients with SCLC did not correlate with prolonged PFS (p=0.53).Following
More news about: Genprex, Inc.
May 26, 2026, 07:30 ET Kazia Therapeutics Expands Ongoing Phase 1b Trial of Paxalisib in Advanced Breast Cancer
chemotherapy. The expanded dataset is expected to provide a more meaningful assessment of objective response rate ("ORR"), progression-free survival ("PFS") and translational biomarkers. Additional clinical trial updates are anticipated throughout 2026 and into 2027."We remain encouraged by the safety
More news about: Kazia Therapeutics Limited
May 26, 2026, 07:23 ET Pierre Fabre Laboratories riceve il parere positivo del CHMP per BRAFTOVI® (encorafenib) in combinazione con cetuximab e FOLFOX (fluorouracile, leucovorin e oxaliplatino) per il trattamento di prima linea di pazienti adulti con carcinoma colorettale metastatico (mCRC) con mutazione BRAFV600E
un miglioramento statisticamente significativo e clinicamente rilevante della sopravvivenza libera da progressione (PFS) rispetto alla chemioterapia con o senza bevacizumab (mediana PFS 12,8 vs 7,1 mesi; hazard ratio [HR] 0,53; intervallo di confidenza [IC] 95%, 0,41–0,68; P<0,001), e ha dimostrato
More news about: Pierre Fabre Laboratories
May 25, 2026, 07:53 ET Pierre Fabre Laboratories erhält positives Gutachten des CHMP für BRAFTOVI® (Encorafenib) in Kombination mit Cetuximab und FOLFOX (Fluorouracil, Leucovorin und Oxaliplatin) zur Erstlinienbehandlung erwachsener Patienten mit BRAFV600E-mutiertem metastasierendem kolorektalen Karzinom (mCRC)
mFOLFOX6 zeigte eine statistisch signifikante und klinisch bedeutsame Verbesserung des progressionsfreien Überlebens (PFS) im Vergleich zur Chemotherapie mit oder ohne Bevacizumab (medianes PFS 12,8 vs. 7,1 Monate; Hazard Ratio [HR] 0,53; 95% Konfidenzintervall [CI], 0,41 bis 0,68; P<0,001) und zeigte
More news about: Pierre Fabre Laboratories
May 25, 2026, 06:11 ET Pierre Fabre Laboratories receives CHMP positive opinion for BRAFTOVI® (encorafenib) in combination with cetuximab and FOLFOX (fluorouracil, leucovorin, and oxaliplatin) for the first-line treatment of adult patients with BRAFV600E-mutant metastatic colorectal cancer (mCRC)
and mFOLFOX6 showed a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared with chemotherapy with or without bevacizumab (median PFS 12.8 vs. 7.1 months; hazard ratio [HR] 0.53; 95% confidence interval [CI], 0.41 to 0.68; P<0.001), and demonstrated
More news about: Pierre Fabre Laboratories